Cart

Equine IFN alpha 1 (Yeast-derived Recombinant Protein) - 25 micrograms

RP0142E-025
$300.00
In Stock
Add to Cart
Bulk quantities of proteins are available. Please contact us for bulk pricing.

Type I interferons comprise a vast and growing group of IFN proteins. Homologous molecules to type I IFNs are found in many species, including all mammals, and some have been identified in birds, reptiles, amphibians and fish species. The mammalian types are designated IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ (also known as limitin). They are mainly involved in innate immune response against viral infection.

IFNα1 Homology Across Species
Equus przewalskii (Przewalski's horse) IFNα1 – 99%
Equus asinus (ass) IFNα1 – 97%
Equine IFN alpha 1 (Yeast-derived Recombinant Protein) - 25 micrograms
Catalog No.:
RP0142E-025
Quantity:
25 ug
Source:
The Equine IFN alpha 1 recombinant protein was produced in yeast and therefore does not have endotoxin, is naturally folded, and post-translationally modified.
MW:
The Equine IFN alpha 1 recombinant protein has a predicted molecular weight of 18.5 kDa.
Protein Sequence:
CDLPHTHSLG NTRVLMLLGQ MRRISPFSCL KDRNDFGFPQ EVFDGNQFRK PQAISAVHET IQQIFHLFST DGSSAAWDES LLDKLYTGLY QQLTELEACL SQEVGVEETP LMNEDSLLAV RRYFQRIALY LQEKKYSPCA WEIVRAEIMR SFSSSTNLPQ S (161)
Country of Origin:
USA
Applications:
The IFN alpha 1 endotoxin-free recombinant protein can be used in cell culture, as a IFN alpha ELISA Standard, and as a Western Blot Control.

31810278

Equine Mx1 Restricts Influenza A Virus Replication by Targeting at Distinct Site of its Nucleoprotein.

Fatima U, Zhang Z, Zhang H, Wang XF, Xu L, Chu X, Ji S, Wang X.

Viruses. 2019 Dec 2;11(12). pii: E1114. doi: 10.3390/v11121114.

Applications: Stimulation of equine monocyte-derived macrophages in culture

Abstract

Interferon-mediated host factors myxovirus (Mx) proteins are key features in regulating influenza A virus (IAV) infections. Viral polymerases are essential for viral replication. The Mx1 protein has been known to interact with viral nucleoprotein (NP) and PB2, resulting in the influence of polymerase activity and providing interspecies restriction. The equine influenza virus has evolved as an independent lineage to influenza viruses from other species. We estimated the differences in antiviral activities between human MxA (huMxA) and equine Mx1 (eqMx1) against a broad range of IAV strains. We found that huMxA has antiviral potential against IAV strains from non-human species, whereas eqMx1 could only inhibit the polymerase activity of non-equine species. Here, we demonstrated that NP is the main target of eqMx1. Subsequently, we found adaptive mutations in the NP of strains A/equine/Jilin/1/1989 (H3N8JL89) and A/chicken/Zhejiang/DTID-ZJU01/2013 (H7N9ZJ13) that confer eqMx1 resistance and sensitivity respectively. A substantial reduction in Mx1 resistance was observed for the two mutations G34S and H52N in H3N8JL89 NP. Thus, eqMx1 is an important dynamic force in IAV nucleoprotein evolution. We, therefore, suggest that the amino acids responsible for Mx1 resistance should be regarded as a robust indicator for the pandemic potential of lately evolving IAVs.

 


31739157

The effect of equine herpesvirus type 4 on type-I interferon signaling molecules.

Oladunni FS, Reedy S, Balasuriya UBR, Horohov DW, Chambers TM.

Vet Immunol Immunopathol. 2020 Jan;219:109971. doi: 10.1016/j.vetimm.2019.109971. Epub 2019 Nov 2.

Applications: Confluent EECs treated with equine IFN alpha t stimulate phosphorylation of STAT proteins.


31024501

Beyond Gut Instinct: Metabolic Short-Chain Fatty Acids Moderate the Pathogenesis of Alphaherpesviruses.

Poelaert KCK, Van Cleemput J, Laval K, Descamps S, Favoreel HW, Nauwynck HJ.

Front Microbiol. 2019 Apr 5;10:723. doi: 10.3389/fmicb.2019.00723. eCollection 2019.

Applications: Equine IFN alpha proteins was used as a positive control in an anti-viral assay.

Abstract

Short-chain fatty acids (SCFA), such as sodium butyrate (SB), sodium propionate (SPr), and sodium acetate (SAc), are metabolic end-products of the fermentation of dietary fibers. They are linked with multiple beneficial effects on the general mammalian health, based on the sophisticated interplay with the host immune response. Equine herpesvirus 1 (EHV1) is a major pathogen, which primarily replicates in the respiratory epithelium, and disseminates through the body via a cell-associated viremia in leukocytes, even in the presence of neutralizing antibodies. Infected monocytic CD172a+ cells and T-lymphocytes transmit EHV1 to the endothelium of the endometrium or central nervous system (CNS), causing reproductive or neurological disorders. Here, we questioned whether SCFA have a potential role in shaping the pathogenesis of EHV1 during the primary replication in the URT, during the cell-associated viremia, or at the level of the endothelium of the pregnant uterus and/or CNS. First, we demonstrated the expression of SCFA receptors, FFA2 and FFA3, within the epithelium of the equine respiratory tract, at the cell surface of immune cells, and equine endothelium. Subsequently, EHV1 replication was evaluated in the URT, in the presence or absence of SB, SPr, or SAc. In general, we demonstrated that SCFA do not affect the number of viral plaques or virus titer upon primary viral replication. Only SB and SPr were able to reduce the plaque latitudes. Similarly, pretreatment of monocytic CD172a+ cells and T-lymphocytes with different concentrations of SCFA did not alter the number of infected cells. When endothelial cells were treated with SB, SPr, or SAc, prior to the co-cultivation with EHV1-inoculated mononuclear cells, we observed a reduced number of adherent immune cells to the target endothelium. This was associated with a downregulation of endothelial adhesion molecules ICAM-1 and VCAM-1 in the presence of SCFA, which ultimately lead to a significant reduction of the EHV1 endothelial plaques. These results indicate that physiological concentrations of SCFA may affect the pathogenesis of EHV1, mainly at the target endothelium, in favor of the fitness of the horse. Our findings may have significant implications to develop innovative therapies, to prevent the devastating clinical outcome of EHV1 infections.


24227834

Equine Tetherin Blocks Retrovirus Release and Its Activity Is Antagonized by Equine Infectious Anemia Virus Envelope Protein.

Yin X, Hu Z, Gu Q, Wu X, Zheng YH, Wei P, Wang X.

J Virol. 2014 Jan;88(2):1259-70. doi: 10.1128/JVI.03148-13. Epub 2013 Nov 13.

Applications: Human embryonic kidney (HEK) 293T cells, equine dermal cells, equine vascular endothelial cells, and HeLa cells were cultured with equine IFN alpha

Abstract
Human tetherin is a host restriction factor that inhibits replication of enveloped viruses by blocking viral release. Tetherin has an unusual topology that includes an N-terminal cytoplasmic tail, a single transmembrane domain, an extracellular domain, and a C-terminal glycosylphosphatidylinositol anchor. Tetherin is not well conserved across species, so it inhibits viral replication in a species-specific manner. Thus, studies of tetherin activities from different species provide an important tool for understanding its antiviral mechanism. Here, we report cloning of equine tetherin and characterization of its antiviral activity. Equine tetherin shares 53%, 40%, 36%, and 34% amino acid sequence identity with feline, human, simian, and murine tetherins, respectively. Like the feline tetherin, equine tetherin has a shorter N-terminal domain than human tetherin. Equine tetherin is localized on the cell surface and strongly blocks human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), and equine infectious anemia virus (EIAV) release from virus-producing cells. The antiviral activity of equine tetherin is neutralized by EIAV envelope protein, but not by the HIV-1 accessory protein Vpu, which is a human tetherin antagonist, and EIAV envelope protein does not counteract human tetherin. These results shed new light on our understanding of the species-specific tetherin antiviral mechanism
 


Ordering Information & Terms and Conditions

Placing Orders
We require a phone number and e-mail address for both the end user of the ordered product and your institution's Accounts Payable representative. This information is only used to help with technical and billing issues.

Via Phone
Please call us at 651-646-0089 between the hours of 8:30 a.m. and 5:30 p.m. CST Mon - Fri.

Via Fax
Orders can be faxed to us 24 hours a day at 651-646-0095.

Via E-mail
Please e-mail orders to orders@KingfisherBiotech.com.

Via Mail
Please mail your order to:
Sales Order Entry
Kingfisher Biotech, Inc.
1000 Westgate Drive
Suite 123
Saint Paul, MN 55114
USA

Product Warranty
Kingfisher Biotech brand products are warranted by Kingfisher Biotech, Inc. to meet stated product specifications and to conform to label descriptions when used, handled and stored according to instructions. Unless otherwise stated, this warranty is limited to one year from date of sale. Kingfisher Biotech’s sole liability for the product is limited to replacement of the product or refund of the purchase price. Kingfisher Biotech brand products are supplied for research applications. They are not intended for medicinal, diagnostic or therapeutic use. The products may not be resold, modified for resale or used to manufacture commercial products without prior written approval from Kingfisher Biotech.

Payment Terms
All prices are subject to change without notice. Payment terms are net thirty (30) days from receipt of invoice. A 1.5% service charge per month is added for accounts past due over 30 days. Prices quoted are U.S. Dollars. The purchaser assumes responsibility for any applicable tax. You will only be charged for products shipped. Products placed on back order will be charged when shipped. If you place an order and fail to fulfill the terms of payment, Kingfisher Biotech, Inc. may without prejudice to any other lawful remedy defer further shipments and/or cancel any order. You shall be liable to Kingfisher Biotech, Inc. for all costs and fees, including attorneys' fees, which Kingfisher Biotech, Inc. may reasonably incur in any actions to collect on your overdue account. Kingfisher Biotech, Inc. does not agree to, and is not bound by, any other terms or conditions such as terms in a purchase order that have not been expressly agreed to in writing signed by a duly authorized officer of Kingfisher Biotech, Inc.

Shipping
Shipping and handling costs are prepaid and added to the invoice. Shipping and handling costs will be charged only on the first shipment in situations where an order contains back ordered products. Kingfisher Biotech, Inc. reserves the right to select the packaging and shipping method for your order, which will ensure the stability of the product and also efficient tracing. Domestic orders will normally be shipped by overnight. Damage during shipment is covered by the warranty provided in these terms and conditions. For international orders, title to the goods passes in the United States when the goods are placed with the shipper. For all orders, the risk of loss of the goods passes when the goods are placed with the shipper.

Returns
Please call customer service before returning any products for refund, credit or replacement. NO returns will be accepted without prior written authorization. Returns are subject to a restocking fee of 20%.